The first subject has been dosed in the phase I trial of BSG005
April 7, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the first volunteer has been dosed with the Company’s proprietary antifungal drug candidate BSG005.Biosergen has enrolled the first subject into the phase I trial of BSG005. This subject will be part of a first cohort of six healthy volunteers. The trial will have up to seven cohorts in the SAD and up to five cohorts in the MAD part of the study. We will report about the successful completion of these cohorts during the next coming months. The successful completion of this phase I trial will be a major milestone